8-K: Vivos Therapeutics Acquires Stake in SOD Sciences

Vivos Therapeutics announces a definitive agreement to acquire an 11% equity stake in SOD Sciences and a 50% co-ownership interest in a pseudohypoxia test, aiming to bolster equity and explore new collaborations.

Summary

• Vivos Therapeutics, Inc. has entered into a Mutual Stock Purchase and Asset Exchange Agreement with SOD Sciences, Inc.
• The agreement involves Vivos issuing 12,000 shares of Series C Convertible Preferred Stock, valued at $12 million, to SOD Sciences.
• In return, Vivos will receive 2,907,338 shares of SOD common stock (representing at least 11% of SOD's fully diluted capital stock) and a 50% co-ownership interest in SOD's pseudohypoxia early-warning test and related patent filings.
• The transaction is expected to close on October 15, 2026, subject to customary conditions.
• This acquisition is anticipated to increase Vivos's stockholders' equity, potentially helping it regain compliance with Nasdaq listing requirements.
• The deal also establishes potential collaboration opportunities with Cleveland Clinic Weston and a marketing arrangement with American Health Associates (AHA).

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, as it addresses Nasdaq listing requirements and opens new strategic avenues, though significant hurdles remain for full realization of benefits.

Positives

• Potential to increase Vivos's stockholders' equity by approximately $8 million on a pro forma basis, aiding compliance with Nasdaq's minimum stockholders equity requirement.
• Acquisition of a 50% co-ownership interest in a proprietary pseudohypoxia early-warning test and related intellectual property.
• Establishes potential strategic alliances with Cleveland Clinic Weston and American Health Associates (AHA), a national medical services provider.
• No cash consideration is paid by Vivos, mitigating immediate financial outflow.
• The Series C Preferred Stock has a fixed conversion price of $0.15, with no price reset or cash settlement features, providing more certainty.
• Vivos will retain 80% of the contribution margin on sales of Vivos products through AHA and Cleveland Clinic Weston channels.

Negatives

• The issuance of Series C Preferred Stock is convertible into up to 80,000,000 shares of common stock, which could lead to significant dilution.
• Closing is contingent on several conditions, including auditor concurrence, consent from the holder of Series B Preferred Stock, and Nasdaq notification, introducing uncertainty.
• The full benefits of the transaction are dependent on the successful negotiation and execution of future definitive agreements, including a joint marketing agreement.
• The clinical utility and commercial success of the jointly owned test are not guaranteed and depend on further validation and regulatory processes.
• The agreement includes an 'exchange cap' of 19.99% of outstanding common stock, requiring stockholder approval for conversions exceeding this limit.

Risks

• The transaction may not close if customary conditions are not met by October 15, 2026.
• Stockholder approval may not be obtained for the issuance of common stock upon conversion of Series C Preferred Stock in excess of the exchange cap.
• The Company's independent registered public accounting firm or Nasdaq may reach conclusions different from those anticipated regarding accounting treatment and compliance.
• The anticipated benefits of the transaction may not be realized.
• Definitive post-closing agreements may not be executed on the anticipated terms or at all.
• The Company may fail to regain or maintain compliance with Nasdaq listing requirements.
• The pseudohypoxia test's clinical utility and commercial viability are subject to validation and regulatory approval.

Future Outlook

The Company anticipates that the transaction, upon closing and if the Series C Preferred Stock is classified in permanent stockholders equity, will increase reported stockholders equity, supporting its efforts to regain compliance with Nasdaq listing rules. Management intends to seek to raise sufficient capital to expand operations and achieve positive cash flow and profitability in early 2027. The Company also expects to pursue collaboration efforts with Cleveland Clinic Weston and American Health Associates, subject to definitive agreements and regulatory requirements, potentially leading to new revenue opportunities.

Management Comments

• "We have been working on this transaction for months and believe the total value accretion to Vivos has the potential to far exceed the immediate dilution from the issuance of the preferred shares."
• "Upon closing, we expect to pursue collaboration efforts contemplated by SODs existing relationship with Cleveland Clinic Weston and with American Health Associates, subject to negotiation and execution of definitive agreements and satisfaction of applicable regulatory and clinical requirements."
• "It is contemplated that Vivos will retain 80% of the contribution margin on sales of Vivos products through those channels, and that the parties will share contribution margin 50/50 on sales of the jointly owned test."
• "That relationship is expected to be solidified in the coming weeks and underway in early 2027, potentially leading to significant new and recurring revenue and high margins opportunities."
• "Sleep apnea is not just a breathing problem. It is a cellular oxygen problem, and the cell remembers."
• "The pseudohypoxia signature tells a patient that their cells have been primed for chronic disease, and ReBalU potentially gives them a way to measure it, treat it, and assess change."
• "Vivos has the patients, the FDA-cleared devices, and the home oxygen test. We have the protocol, the channels, and the science. Together we believe we can turn sleep medicine into an early warning system for chronic disease in America."
• "Our aim is to build a commercial program whose clinical usefulness and operating performance can be measured. Combining our platform with Vivos capabilities creates a potential opportunity; validation and disciplined implementation will determine the results."

Industry Context

StockSavvy.ai notes that this transaction aligns with a growing trend in the healthcare and biotech sectors of strategic partnerships and acquisitions aimed at leveraging complementary technologies and market access. Vivos's focus on sleep apnea and related disorders, combined with SOD Sciences's pseudohypoxia testing platform, suggests an effort to broaden diagnostic capabilities and potentially identify early markers for chronic diseases, a significant area of interest for preventative healthcare.

Comparison to Industry Standards

• The transaction structure, involving preferred stock issuance for an asset and equity stake, is a common method for early-stage or growth-stage companies to finance acquisitions or strategic partnerships without immediate cash outlay.
• The valuation of the Series C Preferred Stock at $12 million for an 11% stake and 50% IP co-ownership is subject to specific due diligence and valuation opinions, as required by Vivos's board and accounting firm, which is standard practice for significant transactions.
• The inclusion of a 19.99% exchange cap on common stock conversion, requiring stockholder approval, is a typical mechanism to manage potential dilution and comply with exchange listing rules, such as those of Nasdaq.
• The revenue sharing model (80/20 for Vivos products, 50/50 for the jointly owned test) is a standard approach in co-marketing and distribution agreements, designed to incentivize both parties based on sales performance.

Corporate Governance

Related Party Transactions

• To the Company's knowledge, no officer, director, or substantial shareholder of the Company has any interest in SOD or in the consideration payable under the Agreement.

Stakeholder Impact

• Shareholders: Potential for increased equity and compliance with Nasdaq rules, but also risk of significant dilution from conversion of Series C Preferred Stock.
• Creditors: Improved financial standing due to increased equity could positively impact creditworthiness.
• Employees: Potential for expanded operations and future growth, contingent on successful integration and capital raising.
• Partners (AHA, Cleveland Clinic): Opportunity for new collaborations and revenue streams, subject to definitive agreements.

Next Steps

• Closing of the Mutual Stock Purchase and Asset Exchange Agreement, expected on October 15, 2026.
• Filing of the Certificate of Designations of Series C Convertible Preferred Stock with the Secretary of State of Delaware.
• Negotiation and execution of a joint marketing or distribution agreement.
• Negotiation and execution of a separate agreement for marketing the ReBalU Protocol to U.S. sleep-testing centers.
• Seeking stockholder approval for the issuance of common stock upon conversion of Series C Preferred Stock in excess of the exchange cap.
• Potential future capital raise to fund operations expansion.

Key Dates

Recommendation

The filing presents a mixed outlook. Positively, it addresses Nasdaq compliance and opens strategic partnership doors. However, the significant potential for dilution from the convertible preferred stock and the contingent nature of future benefits warrant a cautious 'hold' stance until further clarity on Nasdaq compliance, dilution management, and successful integration of the SOD Sciences assets is achieved.

Keywords

pseudohypoxia test, asset exchange, preferred stock, intellectual property, Nasdaq compliance, strategic alliance, stockholder equity, convertible stock